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ABSTRACT
The most commonmethod of diagnosing Obsessive-Compulsive Disorder is the Yale-BrownObsessive
Compulsive Scale, which measures the severity of symptoms without regard to compulsions. However, this scale
is limited to only considering the quantifiable time and energy lost to compulsions. Conversely, current systems
of brain imaging arrest mobility and thus make it virtually impossible to observe compulsions at all, focusing
instead on neurological responses to external stimuli. There is little research which merges both approaches, to
consider the neuro-physiological effects of obsessions as well as the physical response through compulsions. As
such, this research is focused on developing a model of compulsivity based upon neurological chemical pathways.
The objective is to develop a model which would predict, given a set of environmental parameters, the probability
of an individual with OCD performing compulsive behavior and the prevalence of such behavior. By applying
this concept to a neural system known as the worry circuit, a computer program was composed and simulations
run by this program suggest that the likelihood of compulsive behavior can be predicted using a function of
the number of compulsions performed previously. In this model, each neurological agent in the worry circuit,
represented by an automaton, has a certain probability of reacting to a stimulus and moving into one of two
distinct excited states. Based on the final state of the automaton, the agent will send excitatory or inhibitory
signals to surrounding agents, which also have a certain probability of changing states. If the final agent within
the cycle shifts into an excited state, the subject will perform a compulsion. These results may be considered
preliminary, given the sample size of the case study and the primitive nature of the model.
viii
CHAPTER ONE:
INTRODUCTION
Obsessive-CompulsiveDisorder (OCD) is amental disorder which affects approximately 2.3% of people
worldwide at some point in their lives [12]. Individuals with OCD suffer from unwanted and intrusive thoughts
or impulses, known as obsessions, which can cause a great deal of anxiety when persistent. Such individuals may
then feel compelled to complete repetitive behaviors, or compulsions, to ease their anxiety. Typical compulsions
include excessive cleaning of the body or environment, checking, ordering and arranging objects in a precise way,
hoarding, and other physical or mental tics. Additionally, many individuals with OCD have tic-related disorders
which contribute to compulsive behavior, such as trichotillomania or excoriation: picking of the hair or skin,
respectively. Most adults who have OCD are aware that their obsessions and compulsions are irrational, yet
feel that they are unable to stop them. People with OCD may attempt to avoid situations which trigger their
obsessions, or may self-medicate with drugs or alcohol.
Although it is commonly accepted by mental health experts that obsessions and compulsions are
self-perpetuating, there is little research to support this theory. As such, this research proposes that continued
ritualistic behavior, as opposed to calming the OCD sufferer, actually serves to amplify anxiety, which in turn
incites further rituals. We have designed a model which simulates OCD behavior consistent with this theory for
individuals with moderate to severe OCD.
The Problem with Treating OCD as an Anxiety Disorder
The basis for most psychological approaches to OCD is our previous understanding of the neurological
markers and effective treatment of anxiety. However, OCD differs significantly from anxiety disorders in the
exhibition of compulsive behavior to nullify overwhelming anxiety. For this reason, the fifth edition of the
Diagnostic and Statistical Manual (DSM) was updated to separate obsessive-compulsive and related tic disorders
from anxiety disorders [1]. Thereby, it is imprudent to continue measuring current methods of treating OCD by
their efficacy in treating anxiety disorders.
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The most often used method of diagnosing OCD is the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS), which measures the severity of obsessive-compulsive symptoms, without considering the content
of obsessions or the type of compulsions [13]. However, the scale is limited as it rates symptom severity by the
time and energy lost to obsessive and compulsive symptoms, while also relying entirely on self-reporting, which
may be inaccurate. On the other hand, current protocols for brain imaging such as magnetic resonance imaging
(MRI) and computed tomography (CT) scans arrest mobility and make it virtually impossible to objectively
observe physical compulsions while simultaneously scanning neural centers known to induce anxiety.
These limitations influence the health care system by inciting providers to treat only the anxiety aspect of
OCD, while perceiving compulsivity as an inherent side effect. As such, it is necessary to develop new methods
of treating OCD which are specific to the disorder and allow for improved quality of care.
Chemical Involvement in OCD
Every action relies on neurons within the brain communicating with one another. When a typical
neuron is activated by an electrical impulse, it releases a chemical, known as a neurotransmitter, which flows
across a synapse and binds to receptors on the receiving neuron’s dendrites. At this point, the neurotransmitter
causes a new electrical impulse within the receiving dendrite, which may continue the chain [23]. As such,
neurotransmitters may be thought of as chemical messages which are transmitted between neurons. Mental
illnesses, such as OCD, can occur when this chemical process malfunctions or is interrupted.
Serotonin
Serotonin is a neurotransmitter involved mainly in controlling functions such as mood, appetite, and
sleep. Individuals with depression and anxiety have abnormally low levels of serotonin. The belief that serotonin
plays a role in OCD originated from the efficacy of selective serotonin reuptake inhibitors (SSRI) as a treatment
compared with the inefficacy of noradrenergic and dopaminergic reuptake inhibitors [37], which increase the
neurotransmission of noradrenaline and dopamine, respectively. However, the function of the serotonergic
system in OCD pathology is unclear, and the data on the matter is inconsistent. It is plausible that SSRI adjust
the concentration of serotonin to compensate for another malfunctioning neurotransmitter mechanism.
While SSRI are typically used for depression, the American Psychiatric Association (APA) recommends
higher target doses of SSRI to treat OCD than those used to treat major depressive disorder [11], [17]. Patients
must also fail to experience improvement on multiple SSRI at the maximum allowable dose for a minimum of
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two months before being considered treatment resistant [4]. As such, the 20-40% of OCD patients who do not
respond adequately are being treated with significantly higher doses of SSRI for significantly longer periods than
other conditions before being offered alternative treatment [37].
Even if patients are not considered to be resistant, they are still being subjected to a lifetime dose of
SSRI which is often 300% higher than the temporary dose used for other disorders such as depression, and the
average symptom decrease is at most 30-50% [37]. Meta-analysis has shown that these higher doses of SSRI
result in greater side-effect burden and lower tolerability in adults [4].
Glutamate
Glutamate is the most ubiquitous excitatory neurotransmitter in the adult human brain and is involved in
mnemonic functions such as learning and memory formation [23]. Obtaining an accurate estimate of glutamate
concentration from MRI is difficult at the low magnetic field strengths (∼ 1.5 Tesla) used by most MRIs.
Furthermore, glutamate and the amino acid glutamine are difficult to differentiate using MRI, due to their low
concentrations and similar molecular structures [28]. Therefore, most MRI studies of OCD do not discriminate
between glutamate and glutamine, but rather use a composite value Glx [41].
Despite this, several glutamate-related genes have been associated with OCD risk [28]. The efficacy of
SSRI in treating OCD may be due to the inhibitory impact of serotonin on cortico-striatal glutamate release,
as opposed to a causal relationship between serotonin and symptom provocation. Additionally, studies have
found that agents which directly reduce glutamate hyperactivity in the central nervous system are effective as
therapeutic interventions for OCD [27].
Gamma-Aminobutyric Acid
Gamma-aminobutyric acid (GABA) is the most ubiquitous inhibitory neurotransmitter in the adult
human brain, although it is also believed to play an excitatory role in the developing brain [18]. GABA acts by
binding to specific transmembrane receptors in both the pre- and post-synapse plasma membranes of neurons.
This causes the opening of channels to allow the flow of chloride anions into or potassium cations out of the
cell, resulting in a negative change in the transmembrane potential [38].
Previous studies have found altered GABA levels in patients with mood disorders, and lowGABA levels
are believed to correlate with high obsessive-compulsive symptom severity. Research has shown that hepatocyte
growth factor (HGF) increases GABAergic inhibition and that individuals with OCD have significantly less HGF
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and decreased plasma levels of GABA [33]. Although the effect of GABA on symptom provocation is generally
studied for adults, it has been found that age of OCD onset is negatively correlated with GABA saturation in
the medial prefrontal cortex [34].
Dopamine
Dopamine is mainly involved with facilitating the flow of information to the frontal cortex, but it is
also linked to reward systems within the brain [23]. As noted previously, a contraindication to the hypothesis
of serotonin playing a major role in OCD development is that several patients show no significant symptom
improvement on SSRI. However, there is evidence that these patients may benefit from antipsychotics in addition
to SSRI [26]. This suggests that dopaminemay play a role inOCD, as antipsychotics are known to block receptors
in dopamine pathways. Furthermore, several neurological disorders associated with dopaminergic dysfunction,
such as Tourette’s syndrome, also present with OCD symptoms, particularly in adolescents [26]. This suggests
possible common neurobiological mechanisms.
Serotonin tonic inhibition impacts dopamine function in the basal ganglia, which indicates a close
relationship between serotonin and dopamine in OCD symptom provocation [15]. MRI studies show decreased
dopamine D2/3 receptor binding in individuals with OCD, particularly in the ventral striatum [6]. Deep brain
stimulation targeting the nucleus accumbens, which is located in the ventral striatum, induces striatal dopamine
release, and is associated with significant improvement in obsessive-compulsive symptoms. Furthermore, striatal
deep brain stimulation has been known to also increase dopamine in the prefrontal cortex [6].
Brain Circuitry
Compulsive behavior appears to correlate directly with a loss of frontal lobe control. It is commonly
accepted that there is cluster of areas in the brain, known as the “worry circuit,” which incites pathological
compulsions at the expense of impulse control. It is well-established that this circuit includes the orbitofrontal
cortex (OFC), anterior cingulate cortex (ACC), thalamus, and the ventral striatum. Rădulescu andMarra propose
a network of glutamate excitation, GABA inhibition, and dopamine regulation amongst this area, which also
implicates the amygdala and the ventral tegmental area (VTA) [30].
The cortico-striato-thalamo-cortical (CSTC) network has also been implicated in obsessive-compulsive
behavior. This includes the globus pallidus interna (GPi), globus pallidus externa (GPe), substantia nigra, and
the subthalamic nucleus (STN). Multiple single photon emission computed tomography, positron emission
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tomography (PET), and functional magnetic resonance imaging (fMRI) studies have shown increased blood
flow and metabolism in this area [27]. A representation of the chemical pathways within the CSTC network is
given in Figure 1. The leading theory is that increased activity in the direct pathway over the indirect pathway
results in thalamic disinhibition and a self-perpetuating circuit between the thalamus and the OFC [27].
Figure 1: Representation of Cortico-Striato-Thalamo-Cortical Network.*
* In a functional CSTC circuit, glutamatergic signals from the OFC and ACC excite the striatum. Via the direct pathway,
the excited striatum sends additional GABA signals to the GPi and substantia nigra (SNr). This inhibits these areas and
decreases their GABA output to the thalamus, resulting in greater glutamatergic output from the excited thalamus to the
frontal cortex. Via the indirect pathway the striatum instead inhibits the GPe, which decreases its GABA output to the
STN. The STN is may then excite the GPi and SNr, which inhibit the thalamus.
For reference purposes, all neural centers discussed have been labelled in Figures 2 and 3.
Figure 2: Sagittal Brain Cross-section.
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Figure 3: Lateral Brain Cross-section.
Amygdala
The amygdalae are two almond-shaped networks of subnuclei located medially in the temporal lobe.
The amygdalae have been shown to perform a role in processing memory, making decisions, and forming
emotional responses - such as fear and love conditioning. Patients with OCD display significantly increased
functional connectivity of the left amygdala with other centers in the worry circuit in comparison to healthy
subjects, although no structural connectivity differences have been observed [32]. Additionally, OCD patients
showed a negative correlation between symptom severity and structural integrity of white matter tracts between
the amygdalae and other neural centers [32]. These findings suggest that alterations in amygdala structural
connectivity could be associated with alterations in functional connectivity elsewhere, and imply that the
amygdalae play a relatively strong role in OCD development.
Anterior Cinguate Cortex
The anterior cingulate cortex is active in cognitive processes which involve motivation, regulating
emotional responses, and error detection [16]. Hyperactivity within the ACC has an established correlation
with OCD symptom presentation [16] and reduced activity in the area has been shown to correlate with greater
efficacy of SSRI treatment [9]. However, discrepancies with these findings arise when considering severely
drug-resistant OCD; in such cases, it can be assumed that the functional state of the ACC is in constant,
6
gradual flux throughout OCD development [16]. Furthermore, given that nearly all functions performed by the
ACC have contributors in other neural centers, the ACC is considered to have a relatively minor role in OCD
development in comparison to other centers in the worry circuit. This theory will be discussed further during
the robustness section of this thesis.
Globus Pallidus
The globus pallidus externa is the main regulator of the basal ganglia and uses GABAergic neurons to
inhibit the STN, striatum, GPi, and substantia nigra. Via the indirect pathway, the striatum inhibits the GPe,
which decreases its inhibition of the STN. The STN may then excite the GPi and substantia nigra, which inhibit
the thalamus [25].
The globus pallidus interna is one of the two output nuclei for the basal ganglia and utilizes GABAergic
neurons to inhibit the thalamus. Via the direct pathway, the striatum inhibits the GPi, which decreases its
inhibition of the thalamus [25]. Where the direct pathway is excitatory, the indirect pathway is inhibitory. Thus,
it is believed that excessive activity in the direct pathway results in increased obsessive-compulsive severity.
Studies have found smaller globus pallidus volumes in treatment-naïve children, however no differences
have been detected in globus pallidus volumes for adults with OCD compared to healthy controls [19].
Nucleus Accumbens
The nucleus accumbens is part of the ventral striatum in the basal forebrain. The nucleus accumbens
plays a major role in processing rewarding and reinforcing stimuli [24]. Patients with OCD have shown decreased
reward anticipation in the nucleus accumbens when compared with healthy subjects. Additionally, decreased
activity was found to be more pronounced in the nucleus accumbens of patients with contamination fears than
in patients with high-risk assessment [7].
Orbitofrontal Cortex
The orbitofrontal cortex directly contributes to reward-based learning and decision making. Recent
neurobiological models of OCD predict hyperactivity in circuits involving the OFC [3], and lower activity
amongst these circuits is believed to correlate with greater efficacy of SSRI treatment [9]. Such behavior has
been recorded during both symptom provocation and resting-state conditions. Additionally, a resting-state fMRI
study showed that unmedicated patients with OCD had higher distant and local OFC connectivity than healthy
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subjects and significant positive correlations between symptom severity and OFC connectivity [3]. This implies
that the OFC plays a major role in OCD development as compared to other centers in the worry circuit.
Substantia Nigra
The substantia nigra is a large cluster of neurons consisting of two parts: the pars reticulata and the pars
compacta. The pars compacta synthesizes dopamine and sends it to either the caudate nucleus or the putamen.
The dopaminergic cells then inhibit neurons in these areas and influence the GABAergic neuronal output to the
pars reticulata, which in turn projects to the thalamus [31].
Subthalamic Nucleus
The subthalamic nucleus is believed to play a major role in decision-making and action-selection [22].
Volumes of the STN have not been assessed in patients with OCD due to its small size, which is exceedingly
difficult to measure [19]; however core symptoms of OCD have been attributed to dysfunctional information
processing within the STN. Furthermore, for patients with OCD, research has found electrophysiological
dysfunctions in the associative and limbic areas of the STN, the latter of which is shown to contribute to
checking behavior [22]. Deep brain stimulation of the STN seems to interrupt this disrupted information
processing, leading to a normalization of functional connectivity within the CSTC circuit and a reduction in
symptoms.
Thalamus
The thalamus is a large area of gray matter that is responsible for relaying sensory and motor signals
to the cerebral cortex. Thalamic volume is significantly higher in treatment-naïve patients with OCD than in
healthy subjects, and is positively correlated with symptom severity [19]. Furthermore, reduction in the chemical
N-acetyl-aspartate (NAA) in the left medial thalamus has been correlated with an increase in OCD symptom
severity. However, a significant decrease in the ratios of NAA to choline, creatine, and phosphocreatine has been
found in the medial thalamus of patients with OCD, compared to healthy subjects [8]. Given the thalamus’ role
as the hub for all incoming sensory information, it is believed to play a significant part in OCD development
and relaying stimuli to other centers in the worry circuit.
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Ventral Tegmental Area
The ventral tegmental area’s dopaminergic neurons participate in behavioral disorders, cognition,
motivation, and substance abuse. The activity of dopaminergic neurons in the VTA is also linked to reward
anticipation. Approximately two thirds of the VTA’s neurons are dopaminergic, and most of the remaining
neurons are GABAergic. Recently, it has been discovered that the VTA also contains a large number of
glutamatergic neurons, as well as that dopaminergic neurons can also release glutamate and GABA [39]. Hence,
the VTA outputs a chemically diverse signal.
There is much evidence supporting dopamine’s pathology in OCD provocation. Several studies have
reported reduced D1 and D2 dopamine receptor binding in the striatum [6], [39]. When dopamine antagonists
are used to SSRI, symptom improvement has been observed, especially in the case of patients with comorbid tic
disorders [39]. Thus, abnormalities in dopamine modulation via the VTA could be responsible for some of the
dysfunction observed in OCD.
9
CHAPTER TWO:
CASE STUDY
A case study was performed with the purpose of obtaining data from in vivo exposure therapy for
individuals with OCD, including the number of compulsive rituals performed at varying levels of exposure
severity as well as the amount of time spent performing each ritual. The study was performed over 8 weeks in
the OCD clinic at Kyoto Prefectural University of Medicine in Kyoto, Japan. The data obtained through the case
study was used to assess the precision of the predictive capabilities of the model. No student, faculty, or other
individual affiliated with the University of South Florida was involved in the collection of this data or participant
interactions, but only in the analysis and use of the resulting de-identified data.
Inclusion and Exclusion Criteria
The study considered 7 adults with a primary psychiatric diagnosis of OCD as defined by the DSM-V.
To be enrolled in the study, participants were required to have physical obsessive-compulsive symptoms of at
least moderate severity, defined as at least one observable ritual and a score greater than or equal to 16 on the
Y-BOCS. Participants must also have a score greater than or equal to 4 on the Clinical Global Impressions (CGI)
scale, which provides a stand-alone assessment of the participant’s global mental health functioning prior to the
study [5]. Finally, patients were assessed on the Beck Depression Inventory (BDI-II) to determine severity of
depressive symptoms, if present, but this score was not used for inclusion purposes. A copy of each of these
tests and their rating scales can be found in Appendix B.
Participants were excluded if they had any of the following coexisting disorders: schizophrenia,
bipolar disorder, attention deficit/hyperactivity disorder, neurological disorders including Tourette’s syndrome,
posttraumatic stress disorder, pervasive developmental disorders, or borderline personality disorder. Participants
were not excluded from the study on the basis of medication status, but were requested not to alter medication
regimens during the study period. Table 1 displays the clinical characteristics of the study participants.
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Table 1: Clinical Characteristics of Study Participants.
# of participants CGI Score BDI-II Score Y-BOCS Score
Contamination 5 5.6± 1.14 27.2± 12.93 27.6± 6.19
Checking 2 6.0± 0.00 27.5± 13.44 29.0± 4.24
Methods
Each participant was seen twice over the course of the study. The first visit consisted of the informed
consent procedures and an interview, during which each participant was asked to identify their common triggers
and quantify each (on a 1-10 scale) based on severity of anxiety caused. Participants were also asked to identify
their common rituals. The second visit consisted of an evaluation of Y-BOCS, CGI, and BDI-II scores and a 90
minute in vivo exposure session.
During the exposure session, each participant was exposed to a mild trigger (identified as 1-3 in inducing
anxiety) for 5-30 seconds and asked to freely perform compulsions. The number and length of rituals was noted
and the participant was given a ten minute break, during which their blood pressure and heart rate was measured
to monitor for negative effects of stress. This process was repeated for moderate (4-7 in inducing anxiety)
and severe (8-10) triggers. Although examples can be given of common triggers in each obsessive-compulsive
subtype, such as touching a door handle for individuals with contamination fears, it is impossible to generally
quantify the severity of such triggers, as the anxiety they induce is unique to each individual.
Due to the use of de-identified data from human subjects, an Institutional Review Board (IRB)
exemption was obtained. A letter detailing this exemption can be found in Appendix A.
Results
Given the small sample size for the case study, none of these results may be considered statistically
valid, but merely anecdotal. Initially, all data was compiled and considered in aggregate, as seen in Table 2, which
shows the means and sample standard deviations. Although this allowed for a more accurate approximation
across obsessive-compulsive pathologies, these results were widely varied and difficult to model, due to the
heterogeneous nature of OCD. Furthermore, the sample size limited the number of exposures performed at
each trigger severity. As such, individual outliers, such as that seen in the duration of rituals at trigger severity 8,
had a stronger impact than they would have in a larger sample population.
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Table 2: Compulsive Characteristics at Varying Trigger Severities.
Trigger Severity Number of Compulsions Duration of Rituals (s)
1 2.00± 0.000 26.00± 2.828
2 1.00± 0.000 22.50± 21.920
3 4.50± 3.786 15.89± 19.311
4 1.33± 0.577 38.75± 37.358
5 2.00± 1.414 9.25± 5.315
6 2.50± 2.121 38.60± 16.607
7 10.00± 0.000 3.85± 3.431
8 1.00± 0.000 171.00± 0.000
9 11.00± 11.314 6.77± 9.056
10 11.33± 12.342 29.15± 18.746
The data was then compiled to separate contamination from checking pathologies. This allowed for
analysis of the model’s accuracy, while separating data which may be largely varied and heterogeneous in nature.
As seen in Tables 3 and 4, on average, there were fewer compulsions for those with contamination fears, and
more time spent per ritual. This is likely due to the higher cost of rituals for contamination versus checking; it
takes longer for an individual to satisfactorily complete a decontamination ritual, such as washing their hands,
than to complete a cursory check of a lock, for instance. Additionally, decontamination rituals generally take a
higher physical toll than checking rituals. For example, excessive hand washing can cause severe dermatitis, while
compulsive tooth brushing can lead to torn, bleeding gums and weaken the structural integrity of teeth [14].
Table 3: Compulsive Characteristics for Contamination Pathologies.*
Trigger Severity Number of Compulsions Duration of Rituals (s)
1 2.00± 0.000 26.00± 2.828
2 1.00± 0.000 38.00± 0.000
3 2.67± 1.155 34.13± 14.885
4 1.50± 0.707 47.67± 40.204
5 1.00± 0.000 15.00± 0.000
6 2.50± 2.121 38.60± 16.607
7
8 1.00± 0.000 171.00± 0.000
9 3.00± 0.000 25.00± 6.083
10 11.33± 12.342 29.15± 18.746
* No participants were exposed to a trigger of severity 7.
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Table 4: Compulsive Characteristics for Checking Pathologies.*
Trigger Severity Number of Compulsions Duration of Rituals (s)
1
2 1.00± 0.000 7.00± 0.000
3 10.00± 0.000 1.30± †
4 1.00± 0.000 12.00± 0.000
5 3.00± 0.000 7.33± 4.509
6
7 10.00± 0.000 3.85± 3.431
8
9 19.00± 0.000 3.89± 5.237
10
* No participants were exposed to triggers of severity 1, 6, 8, or 10.
† The rituals at trigger severity 3 were too rapid to be measured individually. Thus standard deviations were not calculated.
Finally, the data was compiled to determine the final number of compulsions performed given each
starting value. This data is the closest to that which would be predicted by our model. As seen in Table 5, the
rate of increase in the final number of compulsions for contamination pathologies was higher for higher numbers
of previous compulsions. However, this behavior was not observed for checking pathologies, perhaps due to
the smaller sample size being unable to outweigh outliers as effectively.
Table 5: Compulsive Characteristics at Varying Previous Compulsions.*
Previous Compulsions
Final Compulsions
Contamination Pathologies Checking Pathologies All Pathologies
0 1.60± 0.548 5.50± 6.364 2.71± 3.251
1 2.00± 0.000 2.00± 0.000 2.00± 0.000
2 4.40± 1.517 5.00± 0.000 4.50± 1.378
3
4 7.00± 0.000 7.00± 0.000
5
6 22.50± 12.021 22.50± 12.021
7
8
9
10 20.00± 0.000 20.00± 0.000
* No participants had 3, 5, 7, 8, or 9 previous compulsions.
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CHAPTER THREE:
PREDICTIVE MODEL
The model utilized in this research was inspired by automata theory, a simple signaling game, and the
Society of Mind metaphor.
Society of Mind
In the late 1960s, Marvin Minsky and Seymour Papert attempted to develop a robot which would build
structures using children’s blocks. The robot consisted of a computer, a mechanical arm, and a camera. However,
it took the designers several years to program hundreds of functions such as Move, See, and Grasp. Thus, Minsky
concluded that no single algorithm could solve even the simplest problems. Rather, it required “hundreds of
other little programs” [20]. This led him to believe that intelligence was not the product of any simple algorithm
for thinking, but of the combined activity of great societies of more specialized cognitive processes.
The Society of Mind model views the human mind as a large society of individually simple processes,
known as agents, each specialized to perform a unique function. Each agent is simple by itself, but a combination
of several agents can perform complex tasks. These agents are the fundamental entities which form minds and,
together, yield the abilities which we attribute to minds. However, different agents can be based on different
types of processes with different functions, ways of representing knowledge, and systems for generating results.
Thus, we may think of the entire society as being noncooperative [20]. We adopt this metaphor for our model.
We will first review some extant models.
Signaling Game
A signaling game is a game with two players, a sender and a receiver. The sender can have one of several
types, θs, which determines the set of possible messages. The sender’s type is private information and is not
known by the receiver. The receiver has only a single type, θr , known by both players. The game has two steps:
• The sender plays first. They can play one of several actions, called messages.
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• The receiver plays second, in response to the sender’s message [10].
This theory inspired the method of communication between neural centers for our model.
Automata Theory
Automata theory is a theoretical branch of computer science established in the 20th century, as
mathematicians began developing machines which could imitate certain features of humans and complete
calculations more quickly and reliably. Automata theory concerns computation by finite discrete machines,
called automata. Through automata, computer scientists are able to understand how machines solve problems
and compute functions.
An automaton is an abstract model of a machine that performs computations on an input by moving
through a series of states. At each point of the computation, a transition function reads the input, one symbol
at a time, and determines the next state based on the present symbol and state. As a result, if the computation
reaches an accepting state, it accepts that input.
Our model differs from typical deterministic automata, as we include a probability matrix to determine
state transitions, define an output alphabet as opposed to an accepting state, and utilize a compulsions counter,
designed as a stack.
Probabilistic Automata
Specifically, we are utilizing probabilistic automata. Introduced by Michael Rabin in 1963, a probabilistic
automaton is formally defined as a 5-tuple 〈Q,Σ,M, q0, F 〉 where:
• Q = {q0, ..., qn} is a finite set of states.
• Σ is a finite set called the input alphabet.
• M is a functionM : Q×Σ→ [0, 1](n+1)×1 such that, for (q, σ) ∈ Q×Σ,
M(q, σ) =
(
p0(q, σ), ..., pn(q, σ)
)
, 0 ≤ pi(q, σ),
∑
i
pi(q, σ) = 1,
where [0, 1] is the closed unit interval 0 ≤ x ≤ 1, [0, 1]n+1 is the set of all n + 1-tuples (x0, ..., xn)
where 0 ≤ xi ≤ 1, and [0, 1](n+1)×1 is the transition probabilities table.
• q0 ∈ Q is the initial state.
• F ⊆ Q is the set of accepting states.
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When in state q, for any input σ ∈ Σ, the automatonmay enter any one of the states qi ∈ Q and the probability of
entering qi is the (i+1)st coordinate pi(q, σ) ofM(q, σ). These transition probabilities pi(q, σ) are independent
of time and previous inputs [29].
Note that probabilistic automata accept or reject each input. Our model does not accept or reject inputs,
nor contain a set of accepting states. However, we adopt the function M to determine the probability of each
automaton shifting states.
Moore Machines
Our model is designed similarly to a network of Moore machines. Developed in 1956 by EdwardMoore,
aMooremachine is a finite-state machine whose output values are determined solely by its current state. AMoore
machine can be formally defined as a 6-tuple 〈Q, q0,Σ,Λ, T,G〉 where:
• Q = {q0, ..., qn} is a finite set of states.
• q0 ∈ Q is the initial state.
• Σ is the input alphabet.
• Λ is the output alphabet.
• T is a transition function T : Q× Σ→ Q mapping a state and the input alphabet to the next state.
• G is an output function G : Q→ Λ mapping each state to the output alphabet [21].
Our model differs from a network of Moore machines only by the use of a Rabin-esque probability functionM
in place of the transition function, T . As such, we deem this a Rabin-Moore automata system. Similar systems
were designed by Stark utilizing cellular automata ([35], [36]), however Stark updated random subsets of automata
at each time increment, whereas our model updates each automaton individually, thus, consideration must be
made for executing order.
Model
Each center within the worry circuit was modeled by an automaton with up to three states: unexcited,
excited, or highly excited. These automata communicate with one another through a round robin-style network
with a central stack, defined below. At the head of the network is the thalamus which sends a signal around the
network until reaching the OFC. The model is designed to predict the final number of compulsions performed
in a run of cycles, given the number of compulsions performed previously and the severity of the external trigger.
A run terminates when a cycle ends without producing a compulsion.
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Network
The communication between the automata in this model is given by a system which we call a
Round-Robin Network with Stack (RRNS). We call this a “round-robin” network because each automaton
(defined below) is called individually in circular order, and the “stack” refers to an object the automata can read
from or write onto. We formally define an RRNS as a 5-tuple 〈D,α,Π,Σ, ζ〉, where:
• D = 〈V,A〉 is a digraph, with vertices, V , and arcs, A;
• α is a function such that, ∀v ∈ V , α(v) is an automaton defined by a 9-tuple, below;
• Π is the stack alphabet;
• Σ is the communication alphabet;
• ζ , a bijection, ζ : {1, ..., |V |} → V , is the schedule.
We now characterize the automata α(v), v ∈ V .
Automata
For every v ∈ V , let In(v) = {u ∈ V : arc(u, v)} and Out(v) = {u ∈ V : arc(v, u)}. For every
automaton, α(v), let Inα(v) = {α(u) : u ∈ In(v)} and Outα(v) = {α(u) : u ∈ Out(v)}. We define each
α(v), over alphabet Σ, as a 9-tuple
〈
Qα(v),Θα(v),Λα(v), γ,Πα(v),Mα(v), δα(v), q0, Gα(v)
〉
, where:
• Qα(v) = {q0, ..., qn} is the finite set of states;
• Θα(v) = {{(α(u), α(v), σi) : α(u) ∈ Inα(v)} : ∀i, σi ∈ Σ} is the input alphabet;
• Λα(v) = {{(α(v), α(u), σo) : α(u) ∈ Outα(v)} : ∀o, σo ∈ Σ} is the output alphabet;
• γ ∈ Π* is the content of the stack;
• Πα(v) ⊆ Π is the stack input alphabet. An element HALT is in the stack input alphabet of some
automata to end the cycle;
• Mα(v) is a function Mα(v) : Qα(v) × P(Θα(v)) × γ → [0, 1](n+1)×1 such that, for (q, θ, γ) ∈
Qα(v) × P(Θα(v))× γ,
Mα(v)(q, θ, γ) =
(
p0(q, θ, γ), ..., pn(q, θ, γ)
)
, 0 ≤ pi(q, θ, γ),
∑
i
pi(q, θ, γ) = 1,
where [0, 1](n+1)×1 is the transition probabilities table, P(Θα(v)) denotes the power set of Θα(v), and
pi(q, θ, γ) is the probability of α(v) shifting to state qi;
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• δα(v) is a function, δα(v) : Qα(v)×Π* → Π*, which concatenates the stack with its input δα(v)(q, γ) =
γ + pi, where pi ∈ Πα(v) ∪ {ε}, ε the empty string;
• q0 ∈ Q is the initial state;
• Gα(v) is an output function Gα(v) : Qα(v) → P(Λα(v)) mapping each state into the output alphabet.
Schedule and Updates
For a given RRNS, R, with schedule ζ : {1, ..., |α(v)|} → α(v), let αj = α(ζ(j)). α1 contains the
initial stack, γ0, and input alphabet Θα1 = {}. At time t, if αt is in state q, with stack γ, αt has θ ⊆ Θαt =
{{(αk, αt, σi) : αk ∈ Inαt , k < t} : ∀i, σi ∈ Σ}, shifts into state qi with probability pi(q, θ, γ), and outputs
Gαt(qi) ∈ Λαt = {{(αt, αk, σo) : αk ∈ Outαt , k > t} : ∀o, σo ∈ Σ}. If t ̸= t′, then no change occurs in αt′
at time t. The index, t := tmod |αt|+ 1, updates and the cycle moves to αt+1.
Whenever an automaton αt adds to the stack (i.e. δαt(q, γ) ̸= γ), δαt(q, γ) replaces γ as the stack in
all automata. This continues until HALT ∈ δαt(q, γ). It is important to note that if every automaton in the
network contains an element pi ∈ Πα(v), pi ̸= HALT, then the network can compute indefinitely.
Operation of Network
Each automaton in the network receives input from the automata which communicate with it from
further up the cycle. The automaton then performs a transition function on these inputs to determine its state
and sends outputs to the automata it communicates with further down the cycle. As such, inputs move around
the cycle in a particular order, and outputs are returned to the starting point via the stack.
Example. We give an example of a RRNS 〈D,Ai, {1,HALT}, {−1, 0, 1}, ζ〉with ζ : |Ai| → Ai, i =
1, 2, 3, a digraph, D, and three automata given below:
A1 =
〈{0, 1}, {},ΛA1 , {ε}, {}, (13 , 23) , {ε}, 1, {0 7→ 0, 1 7→ 1}〉,
ΛA1 = {(A1, A2, 0), (A1, A2, 1), (A1, A3, 0), (A1, A3, 1)};
A2 =
〈{0, 1},ΘA2 ,ΛA2 , {ε}, {}, (23 , 13) , {ε}, 0, {0 7→ −1, 1 7→ 0}〉,
ΘA2 = {(A1, A2, 0), (A1, A2, 1)}, ΛA2 = {(A2, A3,−1), (A2, A3, 0)};
A3 =
〈{0, 1, 2},ΘA3 , {}, {ε}, {1,HALT}, (25 , 25 , 15) , {HALT}, 0, {0 7→ −1, 1 7→ 0, 2 7→ 1}〉,
ΘA3 = {(A1, A3, 0), (A1, A3, 1), (A2, A3,−1), (A2, A3, 0)}
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Figure 4: Example Digraph.
It is important to note that GAi for each Ai outputs the same signal to every Aj , i ̸= j.
Step 1: A1 begins in state 1 and stays in state 1, with probability 23 , so A1 outputs (A1, A2, 1), (A1, A3, 1).
Step 2: A2 begins in state 0 and shifts to state 1, with probability 13 , so A2 outputs (A2, A3, 0).
Step 3: A3 begins in state 0 and stays in state 0, with probability 25 , so A3 adds HALT to the stack, and the
computation ends.
Model Specifics
Our model represents the worry circuit as an RRNS, where each neural center of the worry circuit is
represented by an automaton, C , and ΘC and ΛC are based on the glutamate, GABA, and dopamine pathways
between each center. Figure 5 displays the pathways used for this model as a digraph.
Figure 5: Digraph Representing Round Robin Network.
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The content of each automaton in our model is detailed as below.
States. The amygdala and OFC have the set of states, QAm,OFC ={unexcited, excited, highly excited},
while the other automata have the set QC ={unexcited, excited} for C ̸= Am,OFC.
Input Alphabet. The input alphabet for C is the set of messages that can be received by the neural
center, C . Each element contains the center which sent the message, ci, and C , and the excitatory or inhibitory
signal, σ, from the sender. Glutamate, being excitatory, provides σ = 1 or σ = 2. GABA, being inhibitory,
provides σ = −1. Dopamine can provide either σ = 1 or σ = −1 as it is a regulatory chemical. If the center
is unexcited σ = 0.
Output Alphabet. The output alphabet is the set of messages sent by the neural center, C , to all
appropriate recipients. Each message contains C , and the center which receives the message, co, and the
excitatory or inhibitory signal, σ, from the sender. Again, glutamate provides σ = 1 or σ = 2, GABA provides
σ = −1, and dopamine provides σ = 1 or σ = −1. Whether λ includes a 2 depends upon whether “highly
excited” ∈ Q. For example, the message λ = (Am,Th, 1) is an excitatory signal from the amygdala to the
thalamus.
Initial Stack. The initial stack consists of a string of ones, where the cardinality of the stack equals the
number of previous compulsions. Furthermore, each cycle’s γ equals the previous cycle’s δ. As such, δ keeps a
running total of the number of compulsions.
Stack Input Alphabet. Because a compulsion is added every time the OFC becomes excited,ΠOFC =
{1,HALT}, and ΠC = {} for C ̸= OFC.
Probability Matrix. Each input is used in a function, f : Θ → Q, mapping the input into the closed
interval [−0.02, 0.02]. For example, fTh =

0 if θ = (Am,Th, 0)
0.01 if θ = (Am,Th, 1)
provides the thalamus’ f -values for
inputs from the amygdala. The lower bound for the probability distribution is given by b = (w × card(γ)) +
(10w × trigger severity) +∑ fi, where w is 0.001 for the centers in the indirect pathway, and 0.002 elsewhere.
The trigger severity is a fixed value used in all automata. A probability threshold is given by t = 15
∑
f+i , where
f+i is the positive f -values and the coefficient was obtained by comparing simulated with observed results. The
probability value is then randomly chosen via a continuous uniform distribution between b and 1 and, should
this value exceed t, the automaton will become excited. Thus,M(q, θ, γ) =
(
t−b
1−b ,
1−t
1−b
)
.
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Output Function. The output function is based solely on the state of the automaton. If the automaton
is unexcited, it will output either a 0 or a -1 to each of the automata it communicates with. Similarly, an excited
automaton will send a 0 or a 1 and a highly excited automaton will send a 0, a 1, or a 2.
Results
Table 6 shows the model’s simulations for when no compulsions have been performed previously. A
full account of the model’s simulations can be found in Table 13 in Appendix C or in Figure 6 below.
Table 6: Simulated Characteristics with No Previous Compulsions.
Trigger Severity Number of Compulsions
1 1.840± 2.3942
2 1.926± 2.4051
3 2.130± 2.5553
4 2.278± 2.8104
5 2.452± 2.8245
6 2.701± 3.3125
7 3.052± 3.7028
8 3.122± 3.7007
9 3.689± 4.2585
10 4.051± 4.7342
Figure 6: Simulated Characteristics at Varying Previous Compulsions.
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Tests for Robustness
Robustness can be roughly defined as the preservation of the accuracy of a program under variations.
Minor variations, such as reordering, should not create drastic changes in the accuracy of the program’s
functionality. However, major changes, such as removing components, should impact accuracy. Given that our
model works with very small numbers of compulsions (≤ 15) and a high number of iterations (= 1000), we are
recognizing 0.140 compulsions as a considerable difference.
Reordering of Automata
Due to the webbed nature of the network, there are multiple orders in which the cycle could execute.
This robustness test involves rearranging the variable automata and observing the change in results.
The order used in our model is given by the following rules:
• ζ(1) = Thalamus;
• ζ(2), ζ(3), ζ(4) ∈ {ACC, Amygdala, VTA};
• ζ(5) = Nucleus accumbens;
• ζ(6) = GPe;
• ζ(7) = STN;
• ζ(8), ζ(9) ∈ {Substantia nigra, GPi};
• ζ(10) = OFC.
Figure 7: Ordered Representation of Model Brain Circuit.*
* Nodes represent the thalamus, ACC, amygdala, VTA, nucleus accumbens (NAc), GPi, GPe, STN, substantia nigra (SNr),
and OFC.
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Figure 7 shows the order in which the model calls each automaton. Thus, there are 12 possible cycle
options. Table 7 displays all possible options, where Option 1 is the order used in the model.
Table 7: Possible Reorderings of Automata.
Option Order
1 Th→ ACC→ Am→ VTA→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
2 Th→ ACC→ Am→ VTA→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
3 Th→ ACC→ VTA→ Am→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
4 Th→ ACC→ VTA→ Am→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
5 Th→ Am→ ACC→ VTA→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
6 Th→ Am→ ACC→ VTA→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
7 Th→ Am→ VTA→ ACC→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
8 Th→ Am→ VTA→ ACC→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
9 Th→ VTA→ Am→ ACC→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
10 Th→ VTA→ Am→ ACC→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
11 Th→ VTA→ ACC→ Am→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
12 Th→ VTA→ ACC→ Am→ NAc→ GPe→ STN→ GPi→ SNr→ OFC
Table 8: Average Differences in Cycle Results After Reordering.
Option Average Difference in Compulsions
1 0.000± 0.0000
2 0.126± 0.1613
3 0.114± 0.1491
4 0.128± 0.1654
5 0.132± 0.1792
6 0.140± 0.1765
7 0.111± 0.1497
8 0.130± 0.1640
9 0.136± 0.1837
10 0.109± 0.1447
11 0.132± 0.1681
12 0.135± 0.1808
N-Rays Test
The N-rays incident, in which a seemingly vital component was surreptitiously removed from physicist
Prosper-René Blondlot’s equipment during an experiment, resulting in no change in the results, is often used
as a cautionary tale on the dangers of error due to experimenter bias [40]. Thus, the N-rays test for robustness
is conducted by removing a significant part of the model and observing the resulting data. Assuming that the
23
removed portion is not extraneous, significant differences in the results should be observed. Table 9 shows the
orders resulting from the elimination of each automaton.
Table 9: Possible Automata Eliminations.*
Option Eliminated Automaton Revised Order
1 Thalamus ACC→ Am→ VTA→NAc→GPe→ STN→ SNr→GPi→OFC
2 ACC Th→ Am→ VTA→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
3 Amygdala Th→ ACC→ VTA→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
4 VTA Th→ ACC→ Am→ NAc→ GPe→ STN→ SNr→ GPi→ OFC
5 Nucleus accumbens Th→ ACC→ Am→ VTA→ SNr→ GPi→ OFC
6 GPe Th→ ACC→ Am→ VTA→ NAc→ STN→ SNr→ GPi→ OFC
7 STN Th→ ACC→ Am→ VTA→ NAc→ GPe→ SNr→ GPi→ OFC
8 Substantia nigra Th→ ACC→ Am→ VTA→ NAc→ GPe→ STN→ GPi→ OFC
9 GPi Th→ ACC→ Am→ VTA→ NAc→ GPe→ STN→ SNr→ OFC
10 OFC Th→ ACC→ Am→ VTA→ NAc→ GPe→ STN→ SNr→ GPi
* Because the nucleus accumbens is the only entry into the indirect pathway, its elimination also results in the elimination
of the GPe and STN.
Table 10: Average Differences in Cycle Results After Elimination.
Option Eliminated Automaton Average Difference in Compulsions
1 Thalamus 0.131± 0.1746
2 ACC 0.138± 0.1850
3 Amygdala 0.148± 0.2046
4 VTA 0.111± 0.1484
5 Nucleus accumbens 0.119± 0.1515
6 GPe 0.116± 0.1564
7 STN 0.136± 0.1715
8 Substantia nigra 0.129± 0.1751
9 GPi 0.124± 0.1573
10 OFC 0.152± 0.1985
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CHAPTER FOUR:
CONCLUSIONS AND FUTURE WORK
Through the course of this thesis we have addressed issues with the current methods of diagnosing and
treating obsessive-compulsive disorder. The main issues are with the use of magnetic resonance to map brain
functions during symptom provocation. We have raised additional concerns in regard to the use of SSRI to treat
OCD, given its differing pathologies as compared to depression.
An examination of a clinical study performed with OCD patients was also provided. We addressed
the lack of statistical validity, as well as the implications for the heterogeneous nature of different
obsessive-compulsive subtypes. However, we were also able to display a starting point for testing the
accuracy for our model.
Through our model, we have shown that compulsive behavior can be roughly estimated by a function of
previous compulsions performed and the severity of anxiety caused by external stimuli. Furthermore, our model
suggests that compulsive behavior will increase as previous compulsions increase. This implies that compulsivity
may be self-perpetuating.
Analysis
As stated previously, this work is to be considered preliminary and the results anecdotal. The model
displays considerably less variance than observed in the test subjects. This may indicate a greater suitability
for modeling aggregates of patients than generic individuals, but modifications of the model may improve its
simulations of individual patients. Additionally, the results observed from our model appear to correlate more
closely with contamination subtypes than with checking.
Future Work
The main phenomenon observed by our model was the increase in compulsive behavior with increasing
previous compulsions. While this mirrors clinical observations, our model introduced an external counter to
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maintain the value of previous compulsions. It is unlikely that the worry circuit has a dedicated counter with this
function. Therefore, further research is warranted to eliminate the counter, while still accommodating the state
reset, and discover what neural mechanisms actually create this phenomenon.
In addition, the model stops computing whenever a cycle ends without an additional compulsion. While
this provides a clear means of recognizing a break in compulsive behavior, it does not account for individuals
who may avoid compulsions for a short period of time, and then resume. In order to account for such delays, the
model would have to integrate a mechanism for determining the duration of a “pause,” as well as for lowering
the sensitivity to previous compulsions over time.
Finally, as discussed throughout this thesis, OCD is largely heterogeneous. Our model has only been
tested using experimental data for contamination and checking pathologies. Adjustments should be made in
future to accommodate multiple subtypes.
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APPENDIX B:
DIAGNOSTIC SCALES
Beck Depression Inventory
The BDI-II was a 1996 revision of the BDI, which changed many of the diagnostic criteria for
depression [2]. A general example is given below.
BECK DEPRESSION INVENTORY
This depression inventory can be self-scored. The scoring scale is at the end of the questionnaire.
1.
0 I do not feel sad.
1 I feel sad.
2 I am sad all the time and I can’t snap out of it.
3 I am so sad and unhappy that I can’t stand it.
2.
0 I am not particularly discouraged about the future.
1 I feel discouraged about the future.
2 I feel I have nothing to look forward to.
3 I feel the future is hopeless and that things cannot improve.
3.
0 I do not feel like a failure.
1 I feel I have failed more than the average person.
2 As I look back on my life, all I can see is a lot of failures.
3 I feel I am a complete failure as a person.
4.
0 I get as much satisfaction out of things as I used to.
1 I don’t enjoy things the way I used to.
2 I don’t get real satsfaction out of anything anymore.
3 I am dissatisfied or bored with everything.
5.
0 I don’t feel particularly guilty
1 I feel guilty a good part of the time.
2 I feel quite guilty most of the time.
3 I feel guilty all of the time.
6.
0 I don’t feel I am being punished.
1 I feel I may be punished.
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2 I expect to be punished.
3 I feel I am being punished.
7.
0 I don’t feel disappointed in myself.
1 I am disappointed in myself.
2 I am disgusted with myself.
3 I hate myself.
8.
0 I don’t feel I am any worse than anybody else.
1 I am critical of myself for my weaknesses or mistakes.
2 I blame myself all the time for my faults.
3 I blame myself for everything bad that happens.
9.
0 I don’t have any thoughts of killing myself.
1 I have thoughts of killing myself, but I would not carry them out.
2 I would like to kill myself.
3 I would kill myself if I had the chance.
10.
0 I don’t cry any more than usual.
1 I cry more now than I used to.
2 I cry all the time now.
3 I used to be able to cry, but now I can’t cry even though I want to.
11.
0 I am no more irritated by things than I ever was.
1 I am slightly more irritated now than usual.
2 I am quite annoyed or irritated a good deal of the time.
3 I feel irritated all the time.
12.
0 I have not lost interest in other people.
1 I am less interested in other people than I used to be.
2 I have lost most of my interest in other people.
3 I have lost all of my interest in other people.
13.
0 I make decisions about as well as I ever could.
1 I put off making decisions more than I used to.
2 I have greater difficulty in making decisions than I used to.
3 I can’t make decisions at all anymore.
14.
0 I don’t feel that I look any worse than I used to.
1 I am worried that I am looking old or unattractive.
2 I feel there are permanent changes in my appearance that make me look unattractive.
3 I believe that I look ugly.
15.
0 I can work about as well as before.
1 It takes an extra effort to get started at doing something.
2 I have to push myself very hard to do anything.
3 I can’t do any work at all.
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16.
0 I can sleep as well as usual.
1 I don’t sleep as well as I used to.
2 I wake up 1-2 hours earlier than usual and find it hard to go back to sleep.
3 I wake up several hours earlier than I used to and cannot get back to sleep.
17.
0 I don’t get more tired than usual.
1 I get tired more easily than I used to.
2 I get tired from doing almost anything.
3 I am too tired to do anything.
18.
0 My appetite is no worse than usual.
1 My appetite is not as good as it used to be.
2 My appetite is much worse now.
3 I have no appetite at all anymore.
19.
0 I haven’t lost much weight, if any, lately.
1 I have lost more than five pounds.
2 I have lost more than ten pounds.
3 I have lost more than fifteen pounds.
20.
0 I am no more worried about my health than usual.
1 I am worried about physical problems like aches, pains, upset stomach, or constipation.
2 I am very worried about physical problems and it’s hard to think of much else.
3 I am so worried about my physical problems that I cannot think of anything else.
21.
0 I have not noticed any recent change in my interest in sex.
1 I am less interested in sex than I used to be.
2 I have almost no interest in sex.
3 I have lost interest in sex completely.
INTERPRETING THE BECK DEPRESSION INVENTORY
Now that you have completed the questionnaire, add up the score for each of the twenty-one questions by
counting the number to the right of each question you marked. The highest possible total for the whole test
would be sixty-three. This would mean you circled number three on all twenty-one questions. Since the lowest
possible score for each question is zero, the lowest possible score for the test would be zero. This would mean
you circles zero on each question. You can evaluate your depression according to the table below.
Total Score
Levels of Depression:
1-10 = These ups and downs are considered normal
11-16 = Mild mood disturbance
17-20 = Borderline clinical depression
21-30 = Moderate depression
31-40 = Severe depression
over 40 = Extreme depression
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Clinical Global Impressions Scale
The CGI consists of two measures evaluating: (1) the severity of mental illness on a scale from 1 to 7
and (2) the change in mental health from the initiation of treatment. There are no universally accepted scoring
guidelines for the seven diagnostic points of the CGI; rather they were designed to be based upon the clinical
judgment of the diagnosing physician. Tables 11 and 12 display generic guidelines for mental illness severity and
mental health improvement used in clinical research [5].
Table 11: Clinical Global Impressions Severity Scale (CGI-S).
Score Impression Description
1 Normal Not at all ill, symptoms of disorder not present past seven days
2 Borderline mentally ill Subtle or suspected pathology
3 Mildly ill Established symptoms with minimal distress or difficulty in social andoccupational function
4 Moderately ill Overt symptoms causing noticeable functional impairment or distress
5 Markedly ill Intrusive symptoms that distinctly impair social/occupational function orcause intrusive levels of distress
6 Severely ill Disruptive pathology, behavior and function are influenced by symptoms
7 Extremely ill Pathology drastically interferes in many life functions; may be hospitalized
Table 12: Clinical Global Impressions Improvement Scale (CGI-I).
Score Impression Description
1 Very much improved Good level of functioning; minimal symptoms; represents a substantialchange
2 Much improved Notably better with significant reduction of symptoms
3 Minimally improved Slightly better; little or no clinically meaningful reduction of symptoms
4 No change Symptoms remain essentially unchanged
5 Minimally worse Slightly worse but may not be clinically meaningful
6 Much worse Clinically significant increase in symptoms and diminished functioning
7 Very much worse Severe exacerbation of symptoms and loss of functioning
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Yale-Brown Obsessive Compulsive Scale
This scale is designed to rate the severity and type of symptoms in patients with OCD. In general, the
items depend on the patient’s report; however, the final rating is based on the physician’s clinical judgment. The
final score for each item reflects a composite rating of all of the patient’s obsessions or compulsions.
All 19 items are rated, but only items 1-10 (excluding items 1b and 6b) are used to determine the total
Y-BOCS score. The total score is the sum of items 1-10 (excluding 1b and 6b), whereas the obsession subtotal
is the sum of items 1-5 (excluding lb) and the compulsive subtotal is the sum of items 6-10 (excluding 6b) [13].
1. TIME OCCUPIED BY OBSESSIVE THOUGHTS
Q: How much of your time is occupied by obsessive thoughts? [When obsessions occur as brief,
intermittent intrusions, it may be difficult to assess time occupied by them in terms of total hours.
In such cases, estimate time by determining how frequently they occur. Consider both the number
of times the intrusions occur and how many hours of the day are affected.
0 = None.
1 = Mild, less than 1 hr/day or occasional intrusion.
2 = Moderate, 1 to 3 hrs/day or frequent intrusion.
3 = Severe, greater than 3 and up to 8 hrs/day or very frequent intrusion.
4 = Extreme, greater than 8 hrs/day or near constant intrusion.
1b. OBSESSION-FREE INTERVAL (not included in total score)
Q: On the average, what is the longest number of consecutive waking hours per day that you are
completely free of obsessive thoughts?
0 = No symptoms.
1 = Long symptom-free interval, more than 8 consecutive hours/day symptom-free.
2 = Moderately long symptom-free interval, more than 3 and up to 8 consecutive hours/day
symptom-free.
3 = Short symptom-free interval, from 1 to 3 consecutive hours/day symptom-free.
4 = Extremely short symptom-free interval, less than 1 consecutive hour/day symptom-free.
2. INTERFERENCE DUE TO OBSESSIVE THOUGHTS
Q: How much do your obsessive thoughts interfere with your social or work (or role) functioning? Is
there anything that you don’t do because of them?
0 = None.
1 = Mild, slight interference with social or occupational activities, but overall performance not
impaired.
2 = Moderate, definite interference with social or occupational performance, but still manageable.
3 = Severe, causes substantial impairment in social or occupational performance.
4 = Extreme, incapacitating.
3. DISTRESS ASSOCIATED WITH OBSESSIVE THOUGHTS
Q: How much distress do your obsessive thoughts cause you?
0 = None.
1 = Mild, not too disturbing.
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2 = Moderate, disturbing, but still manageable.
3 = Severe, very disturbing.
4 = Extreme, near constant and disabling distress.
4. RESISTANCE AGAINST OBSESSIONS
Q: How much of an effort do you make to resist the obsessive thoughts? How often do you try to disregard
or turn your attention away from these thoughts as they enter your mind? [Only rate effort made to
resist, not success or failure in actually controlling the obsessions.]
0 = Makes an effort to always resist, or symptoms so minimal doesn’t need to actively resist.
1 = Tries to resist most of the time.
2 = Makes some effort to resist.
3 = Yields to all obsessions without attempting to control them, but does so with some reluctance.
4 = Completely and willingly yields to all obsessions.
5. DEGREE OF CONTROL OVER OBSESSIVE THOUGHTS
Q: How much control do you have over your obsessive thoughts? How successful are you in stopping or
diverting your obsessive thinking? Can you dismiss them?
0 = Complete control.
1 = Much control, usually able to stop or divert obsessions with some effort and concentration.
2 = Moderate control, sometimes able to stop or divert obsessions.
3 = Little control, rarely successful in stopping or dismissing obsessions, can only divert attention
with difficulty.
4 = No control, experienced as completely involuntary, rarely able to even momentarily alter
obsessive thinking.
6. TIME SPENT PERFORMING COMPULSIVE BEHAVIORS
Q: How much time do you spend performing compulsive behaviors? [When compulsions occur as brief,
intermittent behaviors, it may difficult to assess time spent performing them in terms of total hours.
In such cases, estimate time by determining how frequently they are performed. Consider both the
number of times compulsions are performed and how many hours of the day are affected. Count
separate occurrences of compulsive behaviors, not number of repetitions.]
0 = None.
1 = Mild (spends less than 1 hr/day performing compulsions), or occasional performance of
compulsive behaviors.
2 = Moderate (spends from 1 to 3 hrs/day performing compulsions), or frequent performance of
compulsive behaviors.
3 = Severe (spends more than 3 and up to 8 hrs/day performing compulsions), or very frequent
performance of compulsive behaviors.
4 = Extreme (spends more than 8 hrs/day performing compulsions), or near constant performance
of compulsive behaviors (too numerous to count).
6b. COMPULSION-FREE INTERVAL (not included in total score)
Q: On the average, what is the longest number of consecutive waking hours per day that you are completely
free of compulsive behavior?
0 = No symptoms.
1 = Long symptom-free interval, more than 8 consecutive hours/day symptom-free.
2 = Moderately long symptom-free interval, more than 3 and up to 8 consecutive hours/day
symptom-free.
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3 = Short symptom-free interval, from 1 to 3 consecutive hours/day symptom-free.
4 = Extremely short symptom-free interval, less than 1 consecutive hour/day symptom-free.
7. INTERFERENCE DUE TO COMPULSIVE BEHAVIORS
Q: How much do your compulsive behaviors interfere with your social or work (or role) functioning? Is
there anything that you don’t do because of the compulsions?
0 = None.
1 = Mild, slight interference with social or occupational activities, but overall performance not
impaired.
2 = Moderate, definite interference with social or occupational performance, but still manageable.
3 = Severe, causes substantial impairment in social or occupational performance.
4 = Extreme, incapacitating.
8. DISTRESS ASSOCIATED WITH COMPULSIVE BEHAVIOR
Q: How would you feel if prevented from performing your compulsions? How anxious would you become?
0 = None.
1 = Mild only slightly anxious if compulsions prevented, or only slight anxiety during performance
of compulsions.
2 = Moderate, reports that anxiety would mount but remain manageable if compulsions prevented,
or that anxiety increases but remains manageable during performance of compulsions.
3 = Severe, prominent and very disturbing increase in anxiety if compulsions interrupted, or
prominent and very disturbing increase in anxiety during performance of compulsions.
4 = Extreme, incapacitating anxiety from any intervention aimed at modifying activity, or
incapacitating anxiety develops during performance of compulsions.
9. RESISTANCE AGAINST COMPULSIONS
Q: How much of an effort do you make to resist the compulsions? [Only rate effort made to resist, not
success or failure in actually controlling the compulsions.]
0 = Makes an effort to always resist, or symptoms so minimal doesn’t need to actively resist.
1 = Tries to resist most of the time.
2 = Makes some effort to resist.
3 = Yields to almost all compulsions without attempting to control them, but does so with some
reluctance.
4 = Completely and willingly yields to all compulsions.
10. DEGREE OF CONTROL OVER COMPULSIVE BEHAVIOR
Q: How strong is the drive to perform the compulsive behavior? How much control do you have over the
compulsions?
0 = Complete control.
1 = Much control, experiences pressure to perform the behavior but usually able to exercise
voluntary control over it.
2 = Moderate control, strong pressure to perform behavior, can control it only with difficulty.
3 = Little control, very strong drive to perform behavior, must be carried to completion, can only
delay with difficulty.
4 =No control, drive to perform behavior experienced as completely involuntary and overpowering,
rarely able to even momentarily delay activity.
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11. INSIGHT INTO OBSESSIONS AND COMPULSIONS
Q: Do you think your concerns or behaviors are reasonable? What do you think would happen if you did
not perform the compulsion(s)? Are you convinced something would really happen?
0 = Excellent insight, fully rational.
1 = Good insight. Readily acknowledges absurdity or excessiveness of thoughts or behaviors but
does not seem completely convinced that there isn’t something besides anxiety to be concerned
about.
2 = Fair insight. Reluctantly admits thoughts or behavior seem unreasonable or excessive, but
wavers. May have some unrealistic fears, but no fixed convictions.
3 = Poor insight. Maintains that thoughts or behaviors are not unreasonable or excessive, but
acknowledges validity of contrary evidence (i.e., overvalued ideas present).
4 = Lacks insight, delusional. Definitely convinced that concerns and behavior are reasonable,
unresponsive to contrary evidence.
12. AVOIDANCE
Q: Have you been avoiding doing anything, going any place, or being with anyone because of your
obsessional thoughts or out of concern you will perform compulsions?
0 = No deliberate avoidance.
1 = Mild, minimal avoidance.
2 = Moderate, some avoidance; clearly present.
3 = Severe, much avoidance; avoidance prominent.
4 = Extreme, very extensive avoidance; patient does almost everything he/she can to avoid
triggering symptoms.
13. DEGREE OF INDECISIVENESS
Q: Do you have trouble making decisions about little things that other people might not think twice about
(e.g., which clothes to put on in the morning; which brand of cereal to buy)?
0 = None.
1 = Mild, some trouble making decisions about minor things.
2 = Moderate, freely reports significant trouble making decisions that others would not think twice
about.
3 = Severe, continual weighing of pros and cons about nonessentials.
4 = Extreme, unable to make any decisions. Disabling.
14. OVERVALUED SENSE OF RESPONSIBILITY
Q: Do you feel very responsible for the consequences of your actions? Do you blame yourself for the
outcome of events not completely in your control?
0 = None.
1 = Mild, only mentioned on questioning, slight sense of over-responsibility.
2 = Moderate, ideas stated spontaneously, clearly present; patient experiences significant sense of
over-responsibility for events outside his/her reasonable control.
3 = Severe, ideas prominent and pervasive; deeply concerned he/she is responsible for events
clearly outside his control. Self-blaming far-fetched and nearly irrational.
4 = Extreme, delusional sense of responsibility.
15. PERVASIVE SLOWNESS/ DISTURBANCE OF INERTIA
Q: Do you have difficulty starting or finishing tasks? Do many routine activities take longer than they
should?
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0 = None.
1 = Mild, occasional delay in starting or finishing.
2 = Moderate, frequent prolongation of routine activities but tasks usually completed. Frequently
late.
3 = Severe, pervasive and marked difficulty initiating and completing routine tasks. Usually late.
4 = Extreme, unable to start or complete routine tasks without full assistance.
16. PATHOLOGICAL
Q: After you complete an activity do you doubt whether you performed it correctly? Do you doubt
whether you did it at all? When carrying out routine activities do you find that you don’t trust your
senses?
0 = None.
1 = Mild, only mentioned on questioning, slight pathological doubt. Examples given may be within
normal range.
2 = Moderate, ideas stated spontaneously, clearly present and apparent in some of patient’s
behaviors; patient bothered by significant pathological doubt. Some effect on performance
but still manageable.
3 = Severe, uncertainty about perceptions or memory prominent; pathological doubt frequently
affects performance.
4 = Extreme, uncertainty about perceptions constantly present; pathological doubt substantially
affects almost all activities.
17. GLOBAL SEVERITY: Interviewer’s judgement of the overall severity of the patient’s illness. Rated from
0 (no illness) to 6 (most severe patient seen)
0 = No illness.
1 = Illness slight, doubtful, transient; no functional impairment.
2 = Mild symptoms, little functional impairment.
3 = Moderate symptoms, functions with effort.
4 = Moderate - Severe symptoms, limited functioning.
5 = Severe symptoms, functions mainly with assistance.
6 = Extremely Severe symptoms, completely nonfunctional.
18. GLOBAL IMPROVEMENT
0 = Very much worse.
1 = Much worse.
2 = Minimally worse.
3 = No change.
4 = Minimally improved.
5 = Much improved.
6 = Very much improved.
19. RELIABILITY
0 = Excellent, no reason to suspect data unreliable.
1 = Good, factor(s) present that may adversely affect reliability.
2 = Fair, factor(s) present that definitely reduce reliability.
3 = Poor, very low reliability.
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APPENDIX C:
ADDITIONAL TABLES
Table 13: Simulated Characteristics at Varying Previous Compulsions.
Trigger Severity Previous Compulsions Final Compulsions
1
0 1.840± 2.3942
1 2.787± 2.3076
2 3.991± 2.4105
3 4.846± 2.2586
4 5.857± 2.3520
5 6.916± 2.4234
6 7.992± 2.5362
7 8.812± 2.2144
8 9.921± 2.1885
9 11.090± 2.5044
10 11.889± 2.3397
2
0 1.926± 2.4051
1 2.984± 2.5168
2 3.985± 2.3888
3 4.820± 2.2425
4 6.100± 2.6921
5 6.809± 2.2471
6 8.005± 2.4143
7 9.126± 2.5657
8 10.028± 2.5651
9 11.113± 2.5339
10 12.047± 2.4287
3
0 2.130± 2.5553
1 3.013± 2.5356
2 4.224± 2.7224
3 5.261± 2.6563
4 6.195± 2.5767
5 7.101± 2.4962
6 8.191± 2.7872
7 9.305± 2.8653
8 10.310± 2.6334
9 11.321± 2.7828
10 12.266± 2.6598
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Table 13 (Continued)
Trigger Severity Previous Compulsions Final Compulsions
4
0 2.278± 2.8104
1 3.285± 2.8488
2 4.326± 2.7293
3 5.207± 2.7014
4 6.235± 2.6572
5 7.380± 2.9736
6 8.381± 3.1054
7 9.440± 2.9143
8 10.413± 2.9697
9 11.330± 2.8441
10 12.589± 3.0954
5
0 2.452± 2.8245
1 3.454± 3.1083
2 4.477± 2.8934
3 5.483± 2.9337
4 6.625± 3.1139
5 7.442± 2.8581
6 8.501± 2.9138
7 9.558± 3.0430
8 10.672± 3.2807
9 11.748± 3.1753
10 12.827± 3.3024
6
0 2.701± 3.3125
1 3.594± 3.0791
2 4.794± 3.2178
3 5.633± 3.0554
4 6.662± 3.1365
5 7.985± 3.4642
6 8.848± 3.4130
7 9.958± 3.5029
8 10.950± 3.5336
9 11.878± 3.2597
10 12.771± 3.4953
7
0 3.052± 3.7028
1 4.017± 3.5746
2 4.801± 3.4224
3 6.187± 3.8271
4 6.739± 3.4425
5 8.162± 3.6167
6 8.911± 3.4443
7 10.065± 3.5428
8 11.244± 3.7455
9 12.298± 3.8026
10 13.197± 3.7739
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Table 13 (Continued)
Trigger Severity Previous Compulsions Final Compulsions
8
0 3.122± 3.7007
1 4.158± 3.9700
2 5.395± 3.8820
3 6.498± 4.2774
4 7.390± 4.3242
5 8.456± 4.0123
6 9.398± 4.0608
7 10.311± 4.1033
8 11.653± 4.7086
9 12.508± 4.0702
10 13.592± 3.9967
9
0 3.689± 4.2585
1 4.709± 7.6038
2 5.909± 4.5707
3 6.733± 4.6255
4 8.037± 4.9912
5 8.792± 4.5567
6 9.771± 4.2236
7 11.155± 5.3426
8 11.787± 4.4251
9 13.269± 5.2148
10 14.257± 5.3018
10
0 4.051± 4.7342
1 5.350± 5.1974
2 6.572± 5.4467
3 7.287± 5.0916
4 8.441± 5.4013
5 9.354± 5.2494
6 10.631± 5.2728
7 11.675± 5.9188
8 13.253± 8.4564
9 13.872± 5.9699
10 14.897± 5.7765
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APPENDIX D:
SOURCE CODE
The Run.m file is the main compiler which calls several functions, each representing a separate
automaton, and then plots the final number of compulsions. The file runs for 1000 iterations to properly
estimate the results.
cd(tempdir); % Open directory
fileID = fopen(’Table.txt’, ’w+’); % Clear table
fclose(fileID);
compulsions = 0; % Define number of compulsions
max_compulsions = 10; % Define maximum number of compulsions
trigger = input(’Trigger severity?\n’); % Input trigger severity
while compulsions <= max_compulsions
iterations = 1; % Define number of iterations
max_iterations = 1000; % Define maximum number of iterations
while iterations <= max_iterations
prior = compulsions;
% Thalamus inputs
ACCTh = 1; % Normal = 0; excited = 1
AmTh = 1; % Normal = 0; excited = 1
VTATh = 1; % Normal = 0; excited = 1; inhibited = -1
NAcTh = 1; % Normal = 0; excited = 1
OFCTh = 1; % Normal = 0; excited = 1
% ACC inputs
ACCACC = 0; % Normal = 0; inhibited = -1
AmACC = 1; % Normal = 0; excited = 1
VTAACC = 1; % Normal = 0; excited = 1; inhibited = -1
OFCACC = 1; % Normal = 0; excited = 1
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% Amygdala inputs
AmAm = 0; % Normal = 0; inhibited = -1
VTAAm = 1; % Normal = 0; excited = 1; inhibited = -1
OFCAm = 0; % Normal = 0; inhibited = -1
% VTA inputs
VTAVTA = 0; % Normal = 0; inhibited = -1
NAcVTA = 1; % Normal = 0; excited = 1
OFCVTA = 1; % Normal = 0; excited = 1
% NAc inputs
AmNAc = 2; % Normal = 0; excited = 1; highly excited = 2
OFCNAc = 2; % Normal = 0; excited = 1; highly excited = 2
% STN inputs
GPeSTN = 0; % Normal = 0; inhibited = -1
% SNr inputs
STNSNr = 1; % Normal = 0; excited = 1
GPiSNr = 1; % Normal = 0; excited = 1; inhibited = -1
% GPi inputs
STNGPi = 1; % Normal = 0; excited = 1
% OFC inputs
OFCOFC = 0; % Normal = 0; inhibited = -1
% Each automaton is called individually
[ThACC, ThAm, ThVTA, ThOFC] = Th(ACCTh, AmTh, VTATh, NAcTh, OFCTh,
compulsions, trigger); % Call thalamus
[ACCTh, ACCACC, ACCAm, ACCVTA] = ACC(ThACC, ACCACC, AmACC, VTAACC,
OFCACC, compulsions, trigger); % Call ACC
[AmTh, AmACC, AmAm, AmVTA, AmNAc, AmOFC] = Am(ThAm, ACCAm, AmAm,
VTAAm, OFCAm, AmNAc, OFCNAc, compulsions, trigger); % Call amygdala
[VTATh, VTAACC, VTAAm, VTAVTA, VTANAc, VTAOFC] = VTA(ThVTA, ACCVTA,
AmVTA, VTAVTA, NAcVTA, OFCVTA, compulsions, trigger); % Call VTA
[NAcTh, NAcVTA, NAcGPe, NAcSNr, NAcGPi] = NAc(AmNAc, VTANAc, OFCNAc,
compulsions, trigger); % Call nucleus accumbens
if NAcGPe == 1 % Indirect pathway
[GPeSTN] = GPe(NAcGPe, compulsions, trigger); % Call GPe
[STNSNr, STNGPi] = STN(GPeSTN, compulsions, trigger); % Call STN
end
[SNrOFC, SNrGPi] = SNr(NAcSNr, STNSNr, GPiSNr, compulsions, trigger); % Call
substantia nigra
[GPiOFC, GPiSNr] = GPi(NAcGPi, STNGPi, SNrGPi, compulsions, trigger); % Call GPi
[OFCTh, OFCACC, OFCAm, OFCVTA, OFCNAc, OFCOFC, probability] = OFC(ThOFC,
AmOFC, VTAOFC, SNrOFC, GPiOFC, OFCOFC, compulsions, trigger); % Call OFC
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%When probability reaches 0.375, a compulsion is performed and the cycle restarts
while probability >= 0.375 && compulsions <= 200 % 200 compulsions is infinite
compulsions = compulsions + 1; % Increase compulsions
% All inputs are reset to normal
ACCTh = 0;
AmTh = 0;
VTATh = 0;
NAcTh = 0;
OFCTh = 0;
ACCACC = 0;
AmACC = 0;
VTAACC = 0;
OFCACC = 0;
AmAm = 0;
VTAAm = 0;
OFCAm = 0;
VTAVTA = 0;
NAcVTA = 0;
OFCVTA = 0;
AmNAc = 0;
OFCNAc = 0;
GPeSTN = 0;
STNSNr = 0;
GPiSNr = 0;
STNGPi = 0;
OFCOFC = 0;
% Each automaton is called again
[ThACC, ThAm, ThVTA, ThOFC] = Th(ACCTh, AmTh, VTATh, NAcTh, OFCTh,
compulsions, trigger);
[ACCTh, ACCACC, ACCAm, ACCVTA] = ACC(ThACC, ACCACC, AmACC,
VTAACC, OFCACC, compulsions, trigger);
[AmTh, AmACC, AmAm, AmVTA, AmNAc, AmOFC] = Am(ThAm, ACCAm,
AmAm, VTAAm, OFCAm, AmNAc, OFCNAc, compulsions, trigger);
[VTATh, VTAACC, VTAAm, VTAVTA, VTANAc, VTAOFC] = VTA(ThVTA,
ACCVTA, AmVTA, VTAVTA, NAcVTA, OFCVTA, compulsions, trigger);
[NAcTh, NAcVTA, NAcGPe, NAcSNr, NAcGPi] = NAc(AmNAc, VTANAc,
OFCNAc, compulsions, trigger);
if NAcGPe == 1
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[GPeSTN] = GPe(NAcGPe, compulsions, trigger);
[STNSNr, STNGPi] = STN(GPeSTN, compulsions, trigger);
end
[SNrOFC, SNrGPi] = SNr(NAcSNr, STNSNr, GPiSNr, compulsions, trigger);
[GPiOFC, GPiSNr] = GPi(NAcGPi, STNGPi, SNrGPi, compulsions, trigger);
[OFCTh, OFCACC, OFCAm, OFCVTA, OFCNAc, OFCOFC, probability] =
OFC(ThOFC, AmOFC, VTAOFC, SNrOFC, GPiOFC, OFCOFC, compulsions, trigger);
end
% Input number of compulsions to table
fileID = fopen(’Table.txt’, ’a+’);
fprintf(fileID,’%6i %6i\r\n’,prior,compulsions);
fclose(fileID);
iterations = iterations + 1; % Increase iterations
compulsions = prior; % Reset compulsions
end
compulsions = compulsions + 1; % Increase compulsions
end
% Collect results
load Table.txt
s0 = Table(1:max_iterations,2);
s1 = Table((max_iterations+1):(2*max_iterations),2);
s2 = Table((2*max_iterations+1):(3*max_iterations),2);
s3 = Table((3*max_iterations+1):(4*max_iterations),2);
s4 = Table((4*max_iterations+1):(5*max_iterations),2);
s5 = Table((5*max_iterations+1):(6*max_iterations),2);
s6 = Table((6*max_iterations+1):(7*max_iterations),2);
s7 = Table((7*max_iterations+1):(8*max_iterations),2);
s8 = Table((8*max_iterations+1):(9*max_iterations),2);
s9 = Table((9*max_iterations+1):(10*max_iterations),2);
s10 = Table((10*max_iterations+1):(11*max_iterations),2);
matrix = [s0, s1, s2, s3, s4, s5, s6, s7, s8, s9, s10];
mean = mean(matrix)
deviation = std(matrix)
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% Thalamus Behavior
function [ThACC, ThAm, ThVTA, ThOFC] = Th(ACCTh, AmTh, VTATh, NAcTh, OFCTh, compulsions,
trigger)
bound = (0.002 * compulsions) + (0.02 * trigger); % Define lower bound
if ACCTh == 1 % ACC excites the thalamus
bound = bound + 0.005;
end
if AmTh == 1 % Amygdala excites the thalamus
bound = bound + 0.01;
end
if VTATh == 1 % VTA excites the thalamus
bound = bound + 0.005;
elseif VTATh == -1 % VTA inhibits the thalamus
bound = bound - 0.01;
end
if NAcTh == 1 % Nucleus accumbens excites the thalamus
bound = bound + 0.005;
end
if OFCTh == 1 % OFC excites the thalamus
bound = bound + 0.01;
end
probability = bound + (1 - bound).*rand; % Selects a random value between the lower bound and 1
if probability >= 0.525 % Thalamus is excited
ThACC = 1; % Thalamus excites the ACC
ThAm = 1; % Thalamus excites the amygdala
ThVTA = 1; % Thalamus excites the VTA
ThOFC = 1; % Thalamus excites the OFC
else % Thalamus is unexcited
ThACC = 0;
ThAm = 0;
ThVTA = 0;
ThOFC = 0;
end
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% Anterior Cingulate Cortex Behavior
function [ACCTh, ACCACC, ACCAm, ACCVTA] = ACC(ThACC, ACCACC, AmACC, VTAACC, OFCACC,
compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if ThACC == 1 % Thalamus excites the ACC
bound = bound + 0.01;
end
if ACCACC == -1 % ACC inhibits itself
bound = bound - 0.01;
end
if AmACC == 1 % Amygdala excites the ACC
bound = bound + 0.01;
end
if VTAACC == 1 % VTA excites the ACC
bound = bound + 0.005;
elseif VTAACC == -1 % VTA inhibits the ACC
bound = bound - 0.01;
end
if OFCACC == 1 % OFC excites the ACC
bound = bound + 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.525 % ACC is excited
ACCTh = 1; % ACC excites the thalamus
ACCACC = 0;
ACCAm = 0;
ACCVTA = 1; % ACC excites the VTA
else % ACC is unexcited
ACCTh = 0;
ACCACC = -1; % ACC inhibits itself
ACCAm = -1; % ACC inhibits the amygdala
ACCVTA = 0;
end
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% Amygdala Behavior
function [AmTh, AmACC, AmAm, AmVTA, AmNAc, AmOFC] = Am(ThAm, ACCAm, AmAm, VTAAm,
OFCAm, AmNAc, OFCNAc, compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if ThAm == 1 % Thalamus excites the amygdala
bound = bound + 0.01;
end
if ACCAm == -1 % ACC inhibits the amygdala
bound = bound - 0.01;
end
if VTAAm == 1 % VTA excites the amygdala
bound = bound + 0.005;
elseif VTAAm == -1 % VTA inhibits the amygdala
bound = bound - 0.01;
end
if OFCAm == -1 % OFC inhibits the amygdala
bound = bound - 0.02;
end
% When the OFC has excites the nucleus accumbens and the amygala excites or highly excites the nucleus
accumbens, self-inhibition inhibits the amygala
if OFCNAc == 1 && AmNAc >= 1 && AmAm == -1
bound = bound - 0.02;
end
% When the OFC highly excites the nucleus accumbens and the amygala excites or highly excites the nucleus
accumbens, self-inhibition inhibits the amygala
if OFCNAc == 2 && AmNAc >= 1 && AmAm == -1
bound = bound - 0.02;
end
% When the OFC highly excites the nucleus accumbens and the amygala has no impact on the nucleus
accumbens, self-inhibition excites the amygala
if OFCNAc == 2 && AmNAc == 0 && AmAm == -1
bound = bound + 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.75 % Amygdala is highly excited
AmTh = 1;
AmACC = 1;
AmAm = 0;
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AmVTA = 1;
AmNAc = 2; % Amygdala highly excites the nucleus accumbens
AmOFC = 1;
elseif probability >= 0.375 % Amygdala is excited
AmTh = 1; % Amygdala excites the thalamus
AmACC = 1; % Amygdala excites the ACC
AmAm = 0;
AmVTA = 1; % Amygdala excites the VTA
AmNAc = 1; % Amygdala excites the nucleus accumbens
AmOFC = 1; % Amygdala excites the OFC
else % Amygdala is unexcited
AmTh = 0;
AmACC = 0;
AmAm = -1; % Amygdala inhibits itself
AmVTA = 0;
AmNAc = 0;
AmOFC = 0;
end
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% Ventral Tegmental Area Behavior
function [VTATh, VTAACC, VTAAm, VTAVTA, VTANAc, VTAOFC] = VTA(ThVTA, ACCVTA, AmVTA,
VTAVTA, NAcVTA, OFCVTA, compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if ThVTA == 1 % Thalamus excites the VTA
bound = bound + 0.01;
end
if ACCVTA == 1 % ACC excites the VTA
bound = bound + 0.005;
end
if AmVTA == 1 % Amygdala excites the VTA
bound = bound + 0.01;
end
if VTAVTA == -1 % VTA inhibits itself
bound = bound - 0.01;
end
if NAcVTA == 1 % Nucleus accumbens excites the VTA
bound = bound + 0.005;
end
if OFCVTA == 1 % OFC excites the VTA
bound = bound + 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.6 % VTA is excited
VTATh = 1; % VTA excites the thalamus
VTAACC = 1; % VTA excites the ACC
VTAAm = 1; % VTA excites the amygdala
VTAVTA = 0;
VTANAc = 1; % VTA excites the nucleus accumbens
VTAOFC = 1; % VTA excites the OFC
else % VTA is unexcited
VTATh = 0;
VTAACC = 0;
VTAAm = 0;
VTAVTA = -1; % VTA inhibits itself
VTANAc = -1; % VTA inhibits the nucleus accumbens
VTAOFC = 0;
end
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% Nucleus Accumbens Behavior
function [NAcTh, NAcVTA, NAcGPe, NAcSNr, NAcGPi] = NAc(AmNAc, VTANAc, OFCNAc,
compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if AmNAc == 2 % Amygdala highly excites the nucleus accumbens
bound = bound + 0.02;
elseif AmNAc == 1 % Amygdala excites the nucleus accumbens
bound = bound + 0.01;
end
if VTANAc == -1 % VTA inhibits the nucleus accumbens
bound = bound - 0.005;
end
if OFCNAc == 2 % OFC highly excites the nucleus accumbens
bound = bound + 0.02;
elseif OFCNAc == 1 % OFC excites the nucleus accumbens
bound = bound + 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.9 % Nucleus accumbens is excited
NAcTh = 1; % Nucleus accumbens excites the thalamus
NAcVTA = 1; % Nucleus accumbens excites the VTA
NAcGPe = 0;
NAcSNr = 1; % Direct pathway
NAcGPi = 1; % Direct pathway
else % Nucleus accumbens is unexcited
NAcTh = 0;
NAcVTA = 0;
NAcGPe = 1; % Indirect pathway
NAcSNr = 0;
NAcGPi = 0;
end
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% Global Pallidus Externa Behavior
function [GPeSTN] = GPe(NAcGPe, compulsions, trigger)
bound = (0.001 * compulsions) + (0.01 * trigger);
if NAcGPe == -1 % Indirect pathway
bound = bound - 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.15 % GPe is excited
GPeSTN = 0;
else % GPe is unexcited
GPeSTN = -1; % GPe inhibits the STN
end
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% Subthalamic Nucleus Behavior
function [STNSNr, STNGPi] = STN(GPeSTN, compulsions, trigger)
bound = (0.001 * compulsions) + (0.01 * trigger);
if GPeSTN == -1 % GPe inhibits STN
bound = bound - 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.15 % STN is excited
STNSNr = 1; % STN excites the substantia nigra
STNGPi = 1; % STN excites the GPi
else % STN is unexcited
STNSNr = 0;
STNGPi = 0;
end
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% Substantia Nigra Behavior
function [SNrGPi, SNrOFC] = SNr(NAcSNr, STNSNr, GPiSNr, compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if NAcSNr == 1 % Direct pathway
bound = bound + 0;
end
if STNSNr == 1 % Indirect pathway
bound = bound + 0.01;
end
if GPiSNr == -1 % GPi inhibits substantia nigra
bound = bound - 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.15 % Substantia nigra is excited
SNrGPi = 0;
SNrOFC = 0;
else % Substantia nigra is unexcited
SNrGPi = -1; % Substantia nigra inhibits the GPi
SNrOFC = -1; % Substantia nigra inhibits the OFC
end
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% Globus Pallidus Interna Behavior
function [GPiSNr, GPiOFC] = GPi(NAcGPi, STNGPi, SNrGPi, compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if NAcGPi == 1 % Direct pathway
bound = bound + 0;
end
if STNGPi == 1 % Indirect pathway
bound = bound + 0.01;
end
if SNrGPi == -1 % Substantia nigra inhibits the GPi
bound = bound - 0.01;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.15 % GPi is excited
GPiSNr = 0;
GPiOFC = 0;
else % GPi is inhibited
GPiSNr = -1; % GPi inhibits the substantia nigra
GPiOFC = -1; % GPi inhibits the OFC
end
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%Orbitofrontal Cortex Behavior
function [OFCTh, OFCACC, OFCAm, OFCVTA, OFCNAc, OFCOFC, probability] = OFC(ThOFC,
AmOFC, VTAOFC, SNrOFC, GPiOFC, OFCOFC, compulsions, trigger)
bound = (0.002 * compulsions) + (0.02 * trigger);
if ThOFC == 1 % Thalamus excites the OFC
bound = bound + 0.01;
end
if AmOFC == 1 % Amygdala excites the OFC
bound = bound + 0.01;
end
if VTAOFC == 1 % VTA excites the OFC
bound = bound + 0.005;
end
if SNrOFC == -1 % Substantia nigra inhibits the OFC
bound = bound - 0.01;
end
if GPiOFC == -1 % GPi inhibits the OFC
bound = bound - 0.01;
end
if OFCOFC == -1 % OFC inhibits itself
bound = bound - 0.02;
end
probability = bound + (1 - bound).*rand;
if probability >= 0.75 % OFC is highly excited
OFCTh = 1;
OFCACC = 1;
OFCAm = 0;
OFCVTA = 1;
OFCNAc = 2; %OFC highly excites the nucleus accumbens
OFCOFC = 0;
elseif probability >= 0.375 % OFC is excited
OFCTh = 1; % OFC excites the thalamus
OFCACC = 1; % OFC excites the ACC
OFCAm = 0;
OFCVTA = 1; % OFC excites the VTA
OFCNAc = 1; % OFC excites the nucleus accumbens
OFCOFC = 0;
else % OFC is unexcited
OFCTh = 0;
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OFCACC = 0;
OFCAm = -1; % OFC inhibits the amygdala
OFCVTA = 0;
OFCNAc = 0;
OFCOFC = -1; % OFC inhibits itself
end
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INDEX
ACC 4–7, 22
Amygdala 4, 6, 19, 20, 22
Anterior cingulate cortex see ACC
Anxiety 1, 2, 11, 25
Automata iii, 15–22, 24
Automata theory 14, 15
Basal ganglia 4, 7
BDI-II 10, 11, 31
Beck Depression Inventory see BDI-II
Blondlot, Prosper-René 23
Cerebral cortex 8
CGI 10, 11, 34
Checking 1, 8, 12, 13, 25, 26
Clinical Global Impressions scale see CGI
Compulsion 1, 2, 4, 11–13, 15, 16, 20–22, 25, 26, 35
Contamination 7, 11–13, 25, 26
Cortico-striato-thalamo-cortical network see CSTC
CSTC 5, 8
Dendrite 2
Depression 2, 3, 25, 31
Dopamine 2, 4, 8, 9, 19, 20
Frontal cortex 4, 5
GABA 3–5, 7–9, 19
Gamma-aminobutyric acid see GABA
Globus pallidus externa see GPe
Globus pallidus interna see GPi
Glutamate 3–5, 9, 19
GPe 4, 7, 22, 24
GPi 4, 7, 22
Magnetic resonance imaging see MRI
Minsky, Marvin 14
MRI 2, 3
Neuron 2, 3, 7–9
Neurotransmitter 2, 3
Nucleus accumbens 4, 7, 22, 24
Obsession 1, 2, 35
OFC 4, 5, 7, 8, 16, 19, 22
Orbitofrontal cortex see OFC
Papert, Seymour 14
Prefrontal cortex 4
Probabilistic automata 15, 16
Ritual 1, 10–13
Robustness 22, 23
Selective serotonin reuptake inhibitors see SSRI
Serotonin 2–4
Signaling game 14
Society of Mind 14
SSRI 2–4, 6, 7, 9, 25
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STN 4, 5, 7, 8, 22, 24
Substantia nigra 4, 7, 8, 22
Subthalamic nucleus see STN
Thalamus 4, 5, 7, 8, 16, 20
Tic disorders 1, 9
Tourette’s syndrome 4, 10
Ventral striatum 4, 5, 7, 9
Ventral tegmental area see VTA
VTA 4, 9, 22
Worry circuit 7, 8, 16, 26
Y-BOCS 2, 10, 11, 35
Yale-Brown Obsessive Compulsive Scale see
Y-BOCS
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